Rhonda Chanson
Internal Medicine · Charleston, SCNPI 1609828706
Payments from drug & device makers
Across 203 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$417
- AbbVie$397
- Novo Nordisk$288
- Boehringer Ingelheim$253
- Astellas Pharma US Inc$200
- Pfizer$200
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,339100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 26 | $417 |
| AbbVie(2 entities) | 26 | $397 |
| Novo Nordisk | 19 | $288 |
| Boehringer Ingelheim | 15 | $253 |
| Astellas Pharma US Inc | 10 | $200 |
| Pfizer | 11 | $200 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $199 |
| GSK | 9 | $158 |
| AstraZeneca | 10 | $137 |
| Novartis | 8 | $136 |
| Johnson & Johnson | 9 | $123 |
| Merck | 8 | $111 |
| Abbott | 4 | $94 |
| Exact Sciences | 4 | $76 |
| Amarin Pharma, Inc. | 4 | $75 |
| Boston Scientific | 3 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $52 |
| Mylan Specialty L.p. | 3 | $43 |
| Bayer | 2 | $41 |
| Amgen | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Biogen | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
How this compares
$3,354 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 66 | $1,148 |
| Atorvastatin Calcium | 54 | $924 |
| Levothyroxine Sodium | 52 | $618 |
| SynthroidLevothyroxine Sodium | 12 | $610 |
| Valsartan | 19 | $451 |
| Amlodipine Besylate | 61 | $432 |
| Losartan Potassium | 22 | $415 |
| Potassium Chloride | 12 | $401 |
| Omeprazole | 16 | $334 |
| Simvastatin | 18 | $260 |
| Metoprolol Succinate | 12 | $221 |
| Escitalopram Oxalate | 13 | $181 |
| Metformin Hcl | 13 | $115 |
| Lisinopril | 14 | $90 |
| Hydrochlorothiazide | 12 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $397 | $61012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Charleston
- Jan BasileCharleston$278K
- James ThomasCharleston$154K
- John CleekCharleston$136K
- Shakaib RehmanCharleston$94K
- Leonard AlsfeldCharleston$91K
- Samuel Schumann IiiCharleston$48K
- Brett TomashitisCharleston$36K
- Scott SandsCharleston$25K
- Laura KinneyCharleston$20K
- Andrew SchreinerCharleston$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.